Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, selective overexpression of androgen receptors in muscle cells increased lean muscle mass and reduced fat mass in transgenic rodents, suggesting a potential target for drug development.

This study found that the steroidal aromatase inhibitor exemestane stimulated proliferation of human osteoblast cells, suggesting both androgen receptor-dependent and independent pathways are involved.

This review discusses several new pharmacological products, including those for cardiovascular prevention and overactive bladder, but notes challenges in defining their therapeutic roles and provides safety updates on existing medications; it reports no new clinical results.

This article reviews the development of selective androgen receptor modulators and myostatin inhibitors as performance-enhancing drugs, highlighting ongoing challenges in achieving truly tissue-selective anabolic agents and reporting no new experimental findings.

This study found evidence of structurally and functionally distinct AR-SARM protein complexes, which may contribute to understanding how SARMs achieve tissue-selective effects.

This study found that AR-007 degrades faster and has a stronger association with hsp70 than AR-014, suggesting it is less stable when bound to the androgen receptor.

This study found that selective androgen receptor modulators (SARMs) significantly inhibited tumor growth and metastasis-promoting factors in AR-positive triple-negative breast cancer models.

This study presented at the ASCO Annual Meeting reported that the epidermal growth factor receptor antibody ABX-EGF showed preliminary efficacy in renal cell cancer patients, with tolerable side effects, while bortezomib demonstrated clinical benefit in a significant proportion of multiple myeloma patients.

This review discusses current challenges in selective androgen receptor modulator discovery and preclinical evaluation and reports no new results, emphasizing the need for basic research to improve safety and selectivity.

In this retrospective pharmacovigilance study, researchers analyzed over 7,900 adverse event reports related to aromatase inhibitors, identifying common side effects and toxicological mechanisms to highlight potential safety concerns in treating postmenopausal hormone receptor-positive breast cancer.

This study found that some synthesized 17-oximino-5-androsten-3β-yl esters demonstrated stronger cytotoxicity and antiandrogenic activity against prostate cancer cells than finasteride.

This study identified compounds 11d and 11k as potential dual 5α-reductase inhibitors and AR antagonists with significant anti-proliferative effects on prostate cancer cell lines, suggesting they may offer therapeutic value.

The study found that ezetimibe effectively reduced prostate enlargement in an animal model of benign prostatic hyperplasia, suggesting it as a potential alternative or complementary treatment.

This abstract provides information on various oral contraceptives, their potential hazardous interactions, and possible side effects, without presenting new research findings.

This article discusses the development and clinical progress of PROTAC technology, particularly focusing on the New Drug Application for vepdegestrant, an estrogen receptor-targeting PROTAC, marking significant advancements in targeted protein degradation therapies.

This article reviews various updates in dermatology, including drug safety alerts and treatment options, and reports no new clinical results.

The BAYONET trial is a phase II study designed to assess the efficacy and safety of combining encorafenib, binimetinib, and cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer that is resistant to encorafenib plus cetuximab; results are not yet reported.

This research investigated the design and synthesis of steroid-based compounds as aromatase inhibitors for breast cancer, finding that certain structural modifications significantly enhance their inhibitory potency.

This article discusses the importance of recognizing adverse drug reactions, methods of prevention, and encourages reporting them to the FDA's MedWatch program; it reports no new results.

This study conducted a large-scale comparison using FAERS data to assess the post-marketing safety profiles of spironolactone, eplerenone, and finerenone, finding unique adverse event patterns for each drug and highlighting the need for personalized safety monitoring and further investigation in other pharmacovigilance databases.

This review provides an overview of clinically approved small molecule drugs targeting androgen receptors and discusses therapeutic applications, without presenting new experimental results.

This study suggests that adding androgens to menopausal hormone therapy may reduce breast cancer risk by counteracting estrogen-driven proliferation in postmenopausal breast tissue.

This study found that novel androgen antagonists incorporating a carborane moiety showed anti-androgenic activity comparable to flutamide in a laboratory setting.

This study found that the compound androstane-17-carboxamide 6 may serve as a lead for new drugs to treat BPH and prostate cancer by reducing the weight of androgen-dependent glands.

This study found that Anovlar effectively reduced pain in severe dysmenorrhea cases and regulated cycles in oligomenorrhea patients, but some side effects and occasional treatment failures were reported.

This case report suggests that spironolactone may induce prostate cancer proliferation in patients on abiraterone acetate, advising against its use for managing treatment-associated side effects in these individuals.

This article reviews current osteoporosis treatments, focusing on the potential of selective androgen receptor modulators and other agents to enhance bone formation, but provides no new clinical data.